GDANSK/LONDON, March 28 (Reuters) - Bank of America analysts on Friday said Novo Nordisk (NOVOb.CO), opens new tab may miss first-quarter expectations, as sales of its blockbuster Wegovy and ...

with an estimated 12-13% sales compound annual growth rate (CAGR). BofA believes that the issues will likely resolve in Novo Nordisk's favor. The firm also discussed the double-edged nature of ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

BofA analysts expect Novo Nordisk's first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year increase, and earnings before interest and taxes (EBIT) to hit DKK 36 billion ...

GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk (NVO) may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt ...